Hapvida signs Roche deal: target for Hapvida stock falls 10.77 percent

Published on 10/14/2026 at 01:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche will invest BRL 250 million in Hapvida's nine-year plan. Hapvida stock receives a BRL 10.52 target after BRL 11.79 on October 2, 2026.

Deals and earnings shape the picture

Hapvida announced a nine-year diagnostic partnership with Roche on October 6, 2026.
Revenue reached USD 240.022 million in the second quarter of 2026, up 55.10 percent year over year.
Fintel reported a BRL 10.52 average target on October 2, 2026, down from BRL 11.79.
Yahoo Finance lists November 11, 2026, as the next earnings date.

Hapvida, BRHAPVACNOR4, Illustration mit AI erstellt.

Hapvida (ISIN BRHAPVACNOR4) signed a nine-year diagnostics partnership with Roche on October 6, 2026, while Hapvida stock received a BRL 10.52 average target after BRL 11.79. The latest deal adds an operating-efficiency angle to a company whose second-quarter revenue rose 55.10 percent year over year but whose EBITDA margin fell to 56.70 percent.

Three events reset the investment case

On August 10, 2026, Hapvida reported second-quarter revenue of USD 240.022 million, up 55.10 percent from the prior-year quarter, while EBITDA increased 36.00 percent to USD 136.179 million. The net loss narrowed to USD 14.933 million from USD 59.460 million, according to Frontier.

On September 30, 2026, Hapvida was reported to be evaluating a potential BRL 1.5 billion hospital sale-leaseback, while net debt to EBITDA stood at 2.49 times in the second quarter, up from 1.26 times a year earlier, according to El Fondo.

On October 6, 2026, the Roche agreement became the latest event. Roche will invest BRL 250 million in technology, while Hapvida may spend BRL 1.5 billion on services and supplies over nine years, according to El Fondo.

What does Roche change for margins?

The program covers two technical centers and 57 hospitals, with 212 new equipment units and 7.5 million laboratory exams processed each month. Those figures give the agreement scale, but the financial test is whether automation can reverse the eight percentage-point EBITDA margin decline recorded between the second quarters of 2025 and 2026.

Fintel reported on October 2, 2026, that the average one-year target fell 10.77 percent from BRL 11.79 to BRL 10.52. Its median target also declined from BRL 11.22 to BRL 8.16, showing that the target revision was broader than a single analyst view, according to Fintel.

Next reporting date is November 11

Yahoo Finance lists November 11, 2026, as Hapvida's next earnings date. The release will offer the next quantified test of the Roche plan, particularly after second-quarter operating cash flow of USD 67.722 million and capital expenditures of USD 33.984 million, figures reported by Yahoo Finance.

Balance sheet remains the counterweight

Hapvida's market capitalization was BRL 4.1 billion as of October 13, 2026, while the B3 listing remained tied to a business with recurring losses and a lower second-quarter margin. The combination of a BRL 1.5 billion asset option, Roche's BRL 250 million investment and the BRL 10.52 consensus target leaves execution and cash generation as the central measures for the next report.